baclofen has been researched along with Anxiety in 44 studies
Anxiety: Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Baclofen did not lead to a differential change in cognitive biases compared with placebo, and trait anxiety levels did not moderate this." | 9.27 | Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein? ( Beraha, EM; Krediet, E; Salemink, E; Wiers, RW, 2018) |
| " A post hoc analysis stratifying according to whether there had been a comorbid anxiety disorder, revealed a beneficial effect of baclofen 30 mg/day versus placebo on time to lapse and relapse (P < 0." | 9.19 | Baclofen for the Treatment of Alcohol Dependence and Possible Role of Comorbid Anxiety. ( Addolorato, G; Baillie, A; Haber, PS; Leggio, L; Leung, S; Morley, KC, 2014) |
| "Previous studies from our laboratory showed that anxiety-related responses induced by nicotine (NIC), measured by the elevated plus maze, were abolished by 2-OH-saclofen (GABAB receptor antagonist) (1 mg/kg; ip) or the lack of GABAB receptors (GABAB1 knockout mice)." | 7.80 | Involvement of GABAB receptors in biochemical alterations induced by anxiety-related responses to nicotine in mice: genetic and pharmacological approaches. ( Balerio, GN; Bettler, B; Pedrón, VT; Varani, AP, 2014) |
| "Adolescents have an increased vulnerability to nicotine and anxiety may play a role in the development of nicotine abuse." | 7.80 | Anxiety status affects nicotine- and baclofen-induced locomotor activity, anxiety, and single-trial conditioned place preference in male adolescent rats. ( Falco, AM; McDonald, CG; Smith, RF, 2014) |
| "We investigated the effects of baclofen, a selective GABA-B receptor agonist, on certain behaviours in rats after short-term hypoxia, as a model of experimentally induced amnesia." | 7.71 | Baclofen prevents hypoxia-induced consolidation impairment for passive avoidance in rats. ( Car, H; Nadlewska, A; Oksztel, R; Wiśniewski, K, 2001) |
| "Baclofen was superior to placebo in the treatment of anxiety, which is of particular interest in view of the recent theories on the mechanism of action of benzodiazepines." | 6.64 | A double-blind trial of baclofen against placebo in the treatment of schizophrenia. ( Andersen, B; Bahr, B; Eliassen, HM; Gulmann, NC, 1976) |
| "BHF177 exhibited pro-convulsion properties only in mice, but not in rats, indicating that this effect may be species-specific." | 5.39 | Comparison of the effects of the GABAB receptor positive modulator BHF177 and the GABAB receptor agonist baclofen on anxiety-like behavior, learning, and memory in mice. ( Cates-Gatto, C; Finn, MG; Kaczanowska, K; Li, X; Markou, A; Risbrough, VB; Roberts, AJ, 2013) |
| "Data from a randomised controlled trial (RCT) (N = 104), in which AUD patients received placebo or baclofen (30 mg/day or 75 mg/day) for 12 weeks, were analysed to determine predictive effects of the following four clinical characteristics: alcoholic liver disease (ALD), baseline alcohol consumption, craving and anxiety." | 5.30 | Clinical Predictors of Response to Baclofen in the Treatment of Alcohol use Disorder: Results from the BacALD Trial. ( Baillie, A; Haber, PS; Morley, KC; Rombouts, SA, 2019) |
| "Baclofen (2 mg/kg) was sedative in both control treated and diazepam-dependent rats, but was ineffective at reversing the decrease in social interaction seen after diazepam withdrawal." | 5.28 | Diazepam withdrawal responses measured in the social interaction test of anxiety and their reversal by baclofen. ( Andrews, N; File, SE; Mabbutt, PS, 1991) |
| "Baclofen did not lead to a differential change in cognitive biases compared with placebo, and trait anxiety levels did not moderate this." | 5.27 | Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein? ( Beraha, EM; Krediet, E; Salemink, E; Wiers, RW, 2018) |
| " Baclofen has been shown to promote abstinence, to reduce craving, and to reduce anxiety in alcohol-dependent individuals, and it promises to be a useful agent, although clinical data are limited at present." | 5.24 | Randomized open-label trial of baclofen for relapse prevention in alcohol dependence. ( Arora, S; Elwadhi, D; Gupta, M; Rastogi, R; Verma, P, 2017) |
| " A post hoc analysis stratifying according to whether there had been a comorbid anxiety disorder, revealed a beneficial effect of baclofen 30 mg/day versus placebo on time to lapse and relapse (P < 0." | 5.19 | Baclofen for the Treatment of Alcohol Dependence and Possible Role of Comorbid Anxiety. ( Addolorato, G; Baillie, A; Haber, PS; Leggio, L; Leung, S; Morley, KC, 2014) |
| "Previous studies from our laboratory showed that anxiety-related responses induced by nicotine (NIC), measured by the elevated plus maze, were abolished by 2-OH-saclofen (GABAB receptor antagonist) (1 mg/kg; ip) or the lack of GABAB receptors (GABAB1 knockout mice)." | 3.80 | Involvement of GABAB receptors in biochemical alterations induced by anxiety-related responses to nicotine in mice: genetic and pharmacological approaches. ( Balerio, GN; Bettler, B; Pedrón, VT; Varani, AP, 2014) |
| "These results showed that nicotine rewarding properties and negative aspects of nicotine withdrawal, such as anxiety-like effects and somatic manifestations, can be modulated by the GABAB receptor activity." | 3.80 | Attenuation by baclofen of nicotine rewarding properties and nicotine withdrawal manifestations. ( Aso, E; Balerio, GN; Maldonado, R; Moutinho, LM; Varani, AP, 2014) |
| "In an attempt to establish a relationship between food intake and fear/anxiety-related behaviours, the goal of this study was to investigate the effect of bilateral injections of GABAA (Muscimol, MUS, doses 25 and 50ng/side) and GABAB (Baclofen, BAC, doses 32 and 64ng/side) receptor agonists in the nucleus accumbens shell (AcbSh) on the level of fear/anxiety-like and feeding behaviours in 24h food-deprived rats." | 3.78 | Effects of GABA ligands injected into the nucleus accumbens shell on fear/anxiety-like and feeding behaviours in food-deprived rats. ( Borges, AC; Faria, MS; Ganzer, L; Januário, AC; Kochenborger, L; Lopes, AP; Marino-Neto, J; Paschoalini, MA, 2012) |
| "This study investigated the effect of GABAA (muscimol, MUSC) and GABAB (baclofen, BACL) agonist receptors microinjected into medial accumbens shell on feeding and the level of fear in free-feeding rats submitted to the elevated plus-maze (EPM), an animal model of anxiety." | 3.74 | GABAA and GABAB agonist microinjections into medial accumbens shell increase feeding and induce anxiolysis in an animal model of anxiety. ( da Cunha, IC; de Lima, TC; Faria, MS; Ferraz, A; Lopes, AP; Neto, JM; Paschoalini, MA; Steffens, SM; Vargas, JC, 2007) |
| "We investigated the effects of baclofen, a selective GABA-B receptor agonist, on certain behaviours in rats after short-term hypoxia, as a model of experimentally induced amnesia." | 3.71 | Baclofen prevents hypoxia-induced consolidation impairment for passive avoidance in rats. ( Car, H; Nadlewska, A; Oksztel, R; Wiśniewski, K, 2001) |
| "Baclofen has been suggested as a potential pharmacotherapy for alcohol use disorder, but the clinical data are conflicting." | 2.84 | Biobehavioral effects of baclofen in anxious alcohol-dependent individuals: a randomized, double-blind, placebo-controlled, laboratory study. ( Amodio, JP; Bollinger, JW; Farinelli, LA; Farokhnia, M; Lee, MR; Leggio, L; Lionetti, TA; Schwandt, ML; Sewell, L; Spero, DE, 2017) |
| "Depression was assessed with Montgomery-Ashberg scale." | 2.80 | [Double blind placebo controlled randomized pilot clinical trial of baclofen (Baclosan®) for alcohol dependence]. ( Alexeeva, YV; Berntsev, VA; Chekhlaty, EI; Kiselev, AS; Krupitsky, EM; Neznanov, NG; Popov, YV; Rybakova, KV; Zubova, EY, 2015) |
| "Baclofen has shown promise in treating substance use disorders and also reduced binge frequency in an open-label trial." | 2.77 | Baclofen reduces binge eating in a double-blind, placebo-controlled, crossover study. ( Boan, J; Corwin, RL; Peters, KF; Ulbrecht, JS, 2012) |
| "Baclofen was associated with a significant reduction in state anxiety (F(1,73)= 5." | 2.75 | Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. ( Flannery, BA; Gallop, R; Garbutt, JC; Kalka-Juhl, L; Kampov-Polevoy, AB, 2010) |
| "Quantitative measurements of spasticity were also taken at each session." | 2.67 | The supraspinal anxiolytic effect of baclofen for spasticity reduction. ( Hinderer, SR, 1990) |
| "Baclofen was superior to placebo in the treatment of anxiety, which is of particular interest in view of the recent theories on the mechanism of action of benzodiazepines." | 2.64 | A double-blind trial of baclofen against placebo in the treatment of schizophrenia. ( Andersen, B; Bahr, B; Eliassen, HM; Gulmann, NC, 1976) |
| "Baclofen is a γ-aminobutyric acid B (GABA-B) agonist which is used increasingly as an off-label treatment." | 2.58 | Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis. ( Jones, A; Rose, AK, 2018) |
| "Baclofen is a new and promising pharmacological compound for the treatment of alcohol dependence (AD)." | 1.46 | Speaking fluently with baclofen? ( Beraha, E; Bodewits, P; van den Brink, W; Wiers, R, 2017) |
| "BHF177 exhibited pro-convulsion properties only in mice, but not in rats, indicating that this effect may be species-specific." | 1.39 | Comparison of the effects of the GABAB receptor positive modulator BHF177 and the GABAB receptor agonist baclofen on anxiety-like behavior, learning, and memory in mice. ( Cates-Gatto, C; Finn, MG; Kaczanowska, K; Li, X; Markou, A; Risbrough, VB; Roberts, AJ, 2013) |
| "Baclofen (2 mg/kg) was sedative in both control treated and diazepam-dependent rats, but was ineffective at reversing the decrease in social interaction seen after diazepam withdrawal." | 1.28 | Diazepam withdrawal responses measured in the social interaction test of anxiety and their reversal by baclofen. ( Andrews, N; File, SE; Mabbutt, PS, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (9.09) | 18.7374 |
| 1990's | 7 (15.91) | 18.2507 |
| 2000's | 9 (20.45) | 29.6817 |
| 2010's | 22 (50.00) | 24.3611 |
| 2020's | 2 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Agabio, R | 1 |
| Baldwin, DS | 1 |
| Amaro, H | 1 |
| Leggio, L | 3 |
| Sinclair, JMA | 1 |
| Zou, HW | 1 |
| Li, ZL | 1 |
| Jing, XY | 1 |
| Wang, Y | 1 |
| Liu, YJ | 1 |
| Li, LF | 1 |
| Farokhnia, M | 1 |
| Schwandt, ML | 1 |
| Lee, MR | 1 |
| Bollinger, JW | 1 |
| Farinelli, LA | 1 |
| Amodio, JP | 1 |
| Sewell, L | 1 |
| Lionetti, TA | 1 |
| Spero, DE | 1 |
| Beraha, E | 1 |
| Bodewits, P | 1 |
| van den Brink, W | 1 |
| Wiers, R | 1 |
| Zarrabian, S | 1 |
| Nasehi, M | 1 |
| Farrahizadeh, M | 1 |
| Zarrindast, MR | 1 |
| Rose, AK | 1 |
| Jones, A | 1 |
| Beraha, EM | 1 |
| Salemink, E | 1 |
| Krediet, E | 1 |
| Wiers, RW | 1 |
| Rombouts, SA | 1 |
| Baillie, A | 2 |
| Haber, PS | 2 |
| Morley, KC | 2 |
| Sweeney, FF | 1 |
| O'Leary, OF | 1 |
| Cryan, JF | 2 |
| Varani, AP | 3 |
| Pedrón, VT | 1 |
| Bettler, B | 1 |
| Balerio, GN | 3 |
| Aso, E | 1 |
| Moutinho, LM | 1 |
| Maldonado, R | 1 |
| Falco, AM | 1 |
| McDonald, CG | 1 |
| Smith, RF | 1 |
| Stratton, MS | 1 |
| Staros, M | 1 |
| Budefeld, T | 1 |
| Searcy, BT | 1 |
| Nash, C | 1 |
| Eitel, C | 1 |
| Carbone, D | 1 |
| Handa, RJ | 1 |
| Majdic, G | 1 |
| Tobet, SA | 1 |
| Leung, S | 1 |
| Addolorato, G | 1 |
| Li, X | 2 |
| Kaczanowska, K | 2 |
| Finn, MG | 2 |
| Markou, A | 2 |
| Risbrough, VB | 2 |
| Krupitsky, EM | 1 |
| Rybakova, KV | 1 |
| Kiselev, AS | 1 |
| Alexeeva, YV | 1 |
| Berntsev, VA | 1 |
| Chekhlaty, EI | 1 |
| Zubova, EY | 1 |
| Popov, YV | 1 |
| Neznanov, NG | 1 |
| Li, C | 2 |
| Yan, Y | 1 |
| Cheng, J | 1 |
| Xiao, G | 1 |
| Gu, J | 1 |
| Zhang, L | 1 |
| Yuan, S | 1 |
| Wang, J | 1 |
| Shen, Y | 1 |
| Zhou, YD | 1 |
| Lu, Y | 1 |
| Li, CJ | 1 |
| Chen, C | 1 |
| Luo, P | 1 |
| Zhou, M | 1 |
| Xu, XL | 1 |
| Lu, Q | 1 |
| He, Z | 1 |
| Guo, LJ | 1 |
| Gupta, M | 1 |
| Verma, P | 1 |
| Rastogi, R | 1 |
| Arora, S | 1 |
| Elwadhi, D | 1 |
| Kheifez, IA | 1 |
| Molodavkin, GM | 1 |
| Voronina, TA | 1 |
| Dugina, YL | 1 |
| Sergeeva, SA | 1 |
| Epstein, OI | 1 |
| Roohbakhsh, A | 1 |
| Keshavarz, S | 1 |
| Hasanein, P | 1 |
| Rezvani, ME | 1 |
| Moghaddam, AH | 1 |
| Garbutt, JC | 1 |
| Kampov-Polevoy, AB | 1 |
| Gallop, R | 1 |
| Kalka-Juhl, L | 1 |
| Flannery, BA | 1 |
| Lopes, AP | 2 |
| Ganzer, L | 1 |
| Borges, AC | 1 |
| Kochenborger, L | 1 |
| Januário, AC | 1 |
| Faria, MS | 2 |
| Marino-Neto, J | 1 |
| Paschoalini, MA | 2 |
| Corwin, RL | 1 |
| Boan, J | 1 |
| Peters, KF | 1 |
| Ulbrecht, JS | 1 |
| Cates-Gatto, C | 1 |
| Roberts, AJ | 1 |
| Sokal, DM | 1 |
| Giarola, AS | 1 |
| Large, CH | 1 |
| Amikishieva, AV | 2 |
| Semendiaeva, SN | 1 |
| Knapp, DJ | 1 |
| Overstreet, DH | 1 |
| Breese, GR | 1 |
| da Cunha, IC | 1 |
| Steffens, SM | 1 |
| Ferraz, A | 1 |
| Vargas, JC | 1 |
| de Lima, TC | 1 |
| Neto, JM | 1 |
| Semendyaeva, SN | 1 |
| Jacobson, LH | 1 |
| Jamous, A | 1 |
| Kennedy, P | 1 |
| Psychol, C | 1 |
| Grey, N | 1 |
| Andrews, N | 2 |
| File, SE | 4 |
| Car, H | 1 |
| Oksztel, R | 1 |
| Nadlewska, A | 1 |
| Wiśniewski, K | 1 |
| Gulmann, NC | 1 |
| Bahr, B | 1 |
| Andersen, B | 1 |
| Eliassen, HM | 1 |
| Shephard, RA | 1 |
| Wedlock, P | 1 |
| Wilson, NE | 1 |
| Zharkovsky, A | 2 |
| Hitchcott, PK | 1 |
| Mabbutt, PS | 1 |
| Gulati, K | 1 |
| Hinderer, SR | 1 |
| Rägo, L | 1 |
| Kiivet, RA | 1 |
| Harro, J | 1 |
| Pŏld, M | 1 |
| Quintero, S | 1 |
| Henney, S | 1 |
| Lawson, P | 1 |
| Mellanby, J | 2 |
| Gray, JA | 2 |
| Buckland, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind, Placebo-Controlled, Randomized Human Laboratory Pilot Study of Baclofen in Anxious Alcoholics[NCT01751386] | Phase 2 | 39 participants (Actual) | Interventional | 2012-12-03 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Amount of alcohol was measured as the number of mini-drinks each participant decided to drink (0-8 mini-drinks). The alcohol content of each mini-drink was calculated based on the participants' total body water, and was designed to raise the blood alcohol concentration by 0.015 g/dL. (NCT01751386)
Timeframe: 2 hours
| Intervention | mini-drinks (Mean) |
|---|---|
| Baclofen | 4.11 |
| Placebo | 4.5 |
2 reviews available for baclofen and Anxiety
| Article | Year |
|---|---|
The influence of anxiety symptoms on clinical outcomes during baclofen treatment of alcohol use disorder: A systematic review and meta-analysis.
Topics: Alcohol Drinking; Alcoholism; Anxiety; Baclofen; GABA-B Receptor Agonists; Humans | 2021 |
Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis.
Topics: Affect; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Anxiety; Baclofen; Craving; Depression; GA | 2018 |
10 trials available for baclofen and Anxiety
| Article | Year |
|---|---|
Biobehavioral effects of baclofen in anxious alcohol-dependent individuals: a randomized, double-blind, placebo-controlled, laboratory study.
Topics: Adult; Alcohol Drinking; Alcoholism; Anxiety; Baclofen; Biobehavioral Sciences; Craving; Double-Blin | 2017 |
Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein?
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Anxiety; Anxiety Disorders; Attentional Bias; | 2018 |
Clinical Predictors of Response to Baclofen in the Treatment of Alcohol use Disorder: Results from the BacALD Trial.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Anxiety; Baclofen; Craving; Dose-Response Rel | 2019 |
Baclofen for the Treatment of Alcohol Dependence and Possible Role of Comorbid Anxiety.
Topics: Adult; Alcohol Abstinence; Alcoholism; Anxiety; Baclofen; Double-Blind Method; Female; GABA-B Recept | 2014 |
[Double blind placebo controlled randomized pilot clinical trial of baclofen (Baclosan®) for alcohol dependence].
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Anxiety; Baclofen; Depression; Double-Blind M | 2015 |
Randomized open-label trial of baclofen for relapse prevention in alcohol dependence.
Topics: Adult; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Anxiety; Baclofen; Craving; GABA-B Receptor | 2017 |
Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Alcohol Drinking; Alcoholism; Anxiety; Baclofen; Depression; Double-Blind Method; | 2010 |
Baclofen reduces binge eating in a double-blind, placebo-controlled, crossover study.
Topics: Adult; Anxiety; Baclofen; Binge-Eating Disorder; Cross-Over Studies; Depression; Double-Blind Method | 2012 |
A double-blind trial of baclofen against placebo in the treatment of schizophrenia.
Topics: Adult; Aminobutyrates; Anxiety; Baclofen; Chlorpromazine; Clinical Trials as Topic; Drug Evaluation; | 1976 |
The supraspinal anxiolytic effect of baclofen for spasticity reduction.
Topics: Adult; Anxiety; Baclofen; Drug Evaluation; Humans; Male; Muscle Spasticity; Random Allocation; Spina | 1990 |
32 other studies available for baclofen and Anxiety
| Article | Year |
|---|---|
The GABA(B1) receptor within the infralimbic cortex is implicated in stress resilience and vulnerability in mice.
Topics: Animals; Anxiety; Avoidance Learning; Baclofen; Behavior, Animal; Disease Models, Animal; Disease Su | 2021 |
Speaking fluently with baclofen?
Topics: Alcohol Abstinence; Alcohol Drinking; Alcoholism; Anxiety; Baclofen; GABA-B Receptor Agonists; Human | 2017 |
The role of CA3 GABA
Topics: 2-Amino-5-phosphonovalerate; Animals; Anxiety; Avoidance Learning; Baclofen; CA3 Region, Hippocampal | 2017 |
Activation but not blockade of GABAB receptors during early-life alters anxiety in adulthood in BALB/c mice.
Topics: Analysis of Variance; Animals; Animals, Newborn; Anxiety; Baclofen; Benzylamines; Defense Mechanisms | 2014 |
Involvement of GABAB receptors in biochemical alterations induced by anxiety-related responses to nicotine in mice: genetic and pharmacological approaches.
Topics: Analysis of Variance; Animals; Anxiety; Baclofen; Disease Models, Animal; Dorsal Raphe Nucleus; Dose | 2014 |
Attenuation by baclofen of nicotine rewarding properties and nicotine withdrawal manifestations.
Topics: Animals; Anxiety; Avoidance Learning; Baclofen; Conditioning, Psychological; GABA-B Receptor Agonist | 2014 |
Anxiety status affects nicotine- and baclofen-induced locomotor activity, anxiety, and single-trial conditioned place preference in male adolescent rats.
Topics: Animals; Anxiety; Association Learning; Baclofen; Behavior, Animal; Cholinergic Agents; Conditioning | 2014 |
Embryonic GABA(B) receptor blockade alters cell migration, adult hypothalamic structure, and anxiety- and depression-like behaviors sex specifically in mice.
Topics: Animals; Anxiety; Baclofen; Cell Movement; Depression; Embryo, Mammalian; Female; GABA-B Receptor An | 2014 |
The GABA(B) receptor positive modulator BHF177 attenuated anxiety, but not conditioned fear, in rats.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Baclofen; Buspirone; Conditioning, Classical; Dose-Response R | 2015 |
Toll-Like Receptor 4 Deficiency Causes Reduced Exploratory Behavior in Mice Under Approach-Avoidance Conflict.
Topics: Analysis of Variance; Animals; Anxiety; Avoidance Learning; Baclofen; Disease Models, Animal; Explor | 2016 |
Activation of GABAB2 subunits alleviates chronic cerebral hypoperfusion-induced anxiety-like behaviours: A role for BDNF signalling and Kir3 channels.
Topics: Animals; Anxiety; Baclofen; Brain-Derived Neurotrophic Factor; CA1 Region, Hippocampal; Carotid Arte | 2016 |
Involvement of the GABA-B system in the mechanism of action of ultralow-dose antibodies to S-100 protein.
Topics: Animals; Anti-Anxiety Agents; Antibodies; Antidepressive Agents; Anxiety; Baclofen; Depression; Diaz | 2008 |
Role of endocannabinoid system in the ventral hippocampus of rats in the modulation of anxiety-like behaviours.
Topics: Amidohydrolases; Animals; Anxiety; Baclofen; Behavior, Animal; Benzamides; Bicuculline; Cannabinoid | 2009 |
Effects of GABA ligands injected into the nucleus accumbens shell on fear/anxiety-like and feeding behaviours in food-deprived rats.
Topics: Animals; Anxiety; Baclofen; Behavior, Animal; Bicuculline; Eating; Fear; Feeding Behavior; Food Depr | 2012 |
GABA(B) receptors involvement in the effects induced by nicotine on anxiety-related behaviour in mice.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Baclofen; Behavior, Animal; GABA-B Receptor Agonists; GABA-B | 2012 |
Comparison of the effects of the GABAB receptor positive modulator BHF177 and the GABAB receptor agonist baclofen on anxiety-like behavior, learning, and memory in mice.
Topics: Animals; Anxiety; Baclofen; Chlordiazepoxide; Dose-Response Relationship, Drug; GABA-B Receptor Agon | 2013 |
Effects of GABA(B), 5-HT(1A), and 5-HT(2) receptor stimulation on activation and inhibition of the rat lateral amygdala following medial geniculate nucleus stimulation in vivo.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Amphetamines; Amygdala; Animals; Anxiety; Baclofen; Evoked P | 2005 |
[Effects of baclofen on anxiety level, sexual motivation and olfactory perception in male mice with different psycho-emotional statuses].
Topics: Aggression; Animals; Anxiety; Baclofen; Emotions; Female; GABA-B Receptor Agonists; Male; Mice; Mice | 2006 |
Baclofen blocks expression and sensitization of anxiety-like behavior in an animal model of repeated stress and ethanol withdrawal.
Topics: Alcohol Drinking; Animals; Anxiety; Baclofen; Body Weight; Central Nervous System Depressants; Diet; | 2007 |
GABAA and GABAB agonist microinjections into medial accumbens shell increase feeding and induce anxiolysis in an animal model of anxiety.
Topics: Analysis of Variance; Animals; Anxiety; Baclofen; Behavior, Animal; Disease Models, Animal; Dose-Res | 2007 |
Effects of baclofen on anxiety, sexual motivation, and olfactory perception in male mice in different psychoemotional states.
Topics: Aggression; Animal Communication; Animals; Anxiety; Baclofen; Dose-Response Relationship, Drug; Emot | 2007 |
Evaluation of the anxiolytic-like profile of the GABAB receptor positive modulator CGP7930 in rodents.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Baclofen; Behavior, Animal; Benzodiazepines; Body Temperature | 2008 |
Psychological and emotional effects of the use of oral baclofen: a preliminary study.
Topics: Adolescent; Adult; Affect; Anxiety; Baclofen; Emotions; Humans; Male; Muscle Spasticity; Psychiatric | 1994 |
Handling history of rats modifies behavioural effects of drugs in the elevated plus-maze test of anxiety.
Topics: Animals; Anxiety; Baclofen; Behavior, Animal; Benzamides; Bridged Bicyclo Compounds; Bridged Bicyclo | 1993 |
Baclofen prevents hypoxia-induced consolidation impairment for passive avoidance in rats.
Topics: Amnesia; Animals; Anxiety; Avoidance Learning; Baclofen; Disease Models, Animal; Exploratory Behavio | 2001 |
Direct evidence for mediation of an anticonflict effect of baclofen by GABAb receptors.
Topics: Amino Acids; Amino Acids, Neutral; Animals; Anxiety; Baclofen; Behavior, Animal; Conflict, Psycholog | 1992 |
Effects of nitrendipine, chlordiazepoxide, flumazenil and baclofen on the increased anxiety resulting from alcohol withdrawal.
Topics: Animals; Anxiety; Baclofen; Chlordiazepoxide; Diazepam; Ethanol; Flumazenil; Interpersonal Relations | 1992 |
Diazepam withdrawal responses measured in the social interaction test of anxiety and their reversal by baclofen.
Topics: Animals; Anxiety; Baclofen; Diazepam; Drug Tolerance; Interpersonal Relations; Male; Rats; Substance | 1991 |
Effects of baclofen and nitrendipine on ethanol withdrawal responses in the rat.
Topics: Aggression; Animals; Anxiety; Baclofen; Diet; Dose-Response Relationship, Drug; Ethanol; Exploratory | 1991 |
Central- and peripheral-type benzodiazepine receptors: similar regulation by stress and GABA receptor agonists.
Topics: Animals; Anxiety; Baclofen; Behavior, Animal; Benzodiazepinones; Binding Sites; Brain; Flunitrazepam | 1989 |
The effects of compounds related to gamma-aminobutyrate and benzodiazepine receptors on behavioural responses to anxiogenic stimuli in the rat: punished barpressing.
Topics: Amobarbital; Animals; Anti-Anxiety Agents; Anxiety; Baclofen; Bicuculline; Carbolines; Chlordiazepox | 1985 |
The effects of compounds related to gamma-aminobutyrate and benzodiazepine receptors on behavioural responses to anxiogenic stimuli in the rat: extinction and successive discrimination.
Topics: Animals; Anxiety; Baclofen; Behavior, Animal; Bicuculline; Chlordiazepoxide; Discrimination Learning | 1986 |